On July 1, the mandatory six-year review of the Canada-United States-Mexico Agreement concluded without renewal. Canada and Mexico had formally indicated they wanted to extend CUSMA for a further term. The United States declined to extend the agreement in its current form. Tariffs already in place stayed in place. Operationally, nothing changed that day.
What changed is structural. Because the extension was not unanimous, CUSMA now goes to joint review annually rather than every six years, for as long as the agreement runs toward its 2036 expiry, according to McMillan LLP's analysis of the review outcome. That detail is worth more in a client conversation than any single tariff line, because six years gave a business owner enough runway to build a valuation, a succession plan, or a buy-sell agreement around a known trade environment. An annual cycle does not.
What Actually Changed for a CCPC With U.S. Revenue
The Bank of Canada's own projection frames the stakes: 2026 GDP finishing roughly 1.5 percentage points below its pre-tariff trajectory, with CUSMA and broader trade uncertainty cited among the leading factors behind a growth forecast of just 0.7% for the year. For a Canadian-controlled private corporation with meaningful U.S.-facing revenue, that uncertainty is no longer a six-year known quantity to plan around once and revisit later. It resets every year the review comes up short of a full extension.
There is a narrower piece of relief. Canada extended the exemption from its Steel Derivative Goods Surtax Order for auto and aerospace inputs from July 1, 2026 to July 1, 2027, giving businesses in those sectors a concrete, if time-limited, planning horizon rather than an open-ended one. A valuation, buy-sell agreement, or estate freeze built around a CCPC's current earnings profile should now flag the next CUSMA review date as an input the same way it would flag a lease renewal or a major customer contract expiry, not treat it as background noise settled back in 2020.
The CRA's own numbers move on a much shorter clock, and one of them is worth watching for a different reason entirely.
The prescribed rate governs the taxable benefit calculation on family income-splitting loans. A loan made while the rate is 3% keeps that rate for its full term even if the CRA rate rises later.
The Prescribed Rate Window Is a Separate, Time-Limited Opportunity
The rate applied to loans between family members has held at 3% since the third quarter of 2025, and the CRA's Q3 2026 announcement kept it flat for a fifth consecutive quarter, its lowest sustained level since the current tightening cycle began in the third quarter of 2022 and peaked at 6% through the first half of 2024. The rate is set quarterly from the average yield on three-month Government of Canada Treasury bills for the first month of the preceding quarter, rounded up. It is not fixed going forward.
That mechanic is what creates the opportunity. A prescribed rate loan set up today for a lower-income spouse or through a family trust locks in the rate in effect at the time the loan is made for the life of that loan, regardless of where the CRA rate goes afterward. For a business owner client with a lower-income spouse, adult children, or an existing family trust structure, the practical question is not whether 3% is attractive. It has been attractive for a year. It is whether this is the quarter the window closes, given that the same Treasury bill yields the rate is calculated from are exposed to the inflation pressure this month's oil price move is already feeding into.
A second CRA number moved this quarter and is easy to miss because it did not change the headline rate. The interest rate for corporate taxpayers' pertinent loans or indebtedness rose to 6.30% for the third quarter, up from 6.20% in the second quarter, a small increase relevant to CCPC clients with intercompany or shareholder loan structures subject to that specific rate. The rate charged on overdue tax, CPP contributions, and EI premiums held at 7%.
Two Different Deadlines, One Client Conversation
These are separate clocks running on separate logic, and a client with a CCPC and a family trust is exposed to both. The CUSMA review cycle argues for revisiting valuation clauses in buy-sell agreements and estate freezes on a shorter, recurring schedule rather than treating a 2020-era number as durable. The prescribed rate sitting at a cycle-low 3% for a fifth straight quarter argues for locking in a family income-splitting loan now, before the same rate mechanics that have kept it low for a year have reason to move. Both conversations belong in the same meeting, for the same client, for different reasons.